A Phase 2 interventional study of CC-97540 and Fludarabine in Lupus Erythematosus, Systemic and Lupus Nephritis, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. Active, not recruiting at 97 sites in 16 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.
Sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.
Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 35th largest by planned enrollment of the 100 interventional ones that give a count, is one of 14 that started in 2025, is one of 34 in phase 2, reaches primary completion later than 20 of the 49 other live ones, and was the 100th registered.
343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.
Browse Lupus Nephritis studies →39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+
Pediatric Nephrology Research Consortium · Sites in United States
Ages up to 18
Hospital for Special Surgery, New York · Sites in United States
Ages 18+
iCell Gene Therapeutics · Sites in United States
Ages 16–70
Akebia Therapeutics · Sites in United States, Brazil
Ages 16+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 47 · Phase 3 17 · Phase 4 7
First in 1994; this study’s year is marked. 14 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 89 is above the median of 48 across 243 interventional studies indexed under Lupus Nephritis.
Median enrollment 50 across the 100 interventional studies, 265 across the 14 observational. Of the 53 that completed or were terminated, 31 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 114 have an industry lead sponsor. The 10 most frequent:
This study is registered under Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company is the lead sponsor of 17 studies on the registry; 12 are open to participants now.
Bristol-Myers Squibb has 6 studies filed under Lupus Nephritis — fewer than ten, so there is no comparison to draw.
11 of the studies in Lupus Nephritis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
| NCT06518668Hospital for Special Surgery, New YorkA Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus | 2026-12 |
| NCT06375993Adicet TherapeuticsA Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease | 2026-12 |
| NCT06217107Morehouse School of MedicineWellness & Workforce Solution for Lupus/Lupus Nephritis | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 114 studies in Lupus Nephritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety and drug levels of CC-97540 in participants with active systemic lupus erythematosus (SLE) including lupus nephritis with inadequate response to glucocorticoids and at least 2 immunosuppressants.
343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.
This study's planned enrollment of 89 is above the median of 48 across 243 interventional studies indexed under Lupus Nephritis.
Browse Lupus Nephritis studies →Juno Therapeutics, Inc., a Bristol-Myers Squibb Company is the lead sponsor of 17 studies on the registry; 12 are open to participants now.
First submitted after Juno Therapeutics, Inc. became part of Bristol-Myers Squibb.
Compared within Lupus Nephritis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lupus Erythematosus, Systemic. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: CC-97540 · Drug: Fludarabine · Drug: Cyclophosphamide
Specified dose on specified days
Also known as: BMS-986353, Zola-cel, Zolacabtagene autoleucel
Specified dose on specified days
Specified dose on specified days
Proportion of participants achieving drug-free Definition of Remission in Systemic Lupus Erythematosus (DORIS) remission
Time frame: At month 6
Complete renal response (CRR) for participants with baseline lupus nephritis (LN)
Time frame: Up to Month 60
Participants with drug-free DORIS remission
Time frame: Up to month 60
CRR for participants with baseline LN
Time frame: Up to month 60
Modified CRR for participants with baseline LN
Time frame: Up to month 60
Number of participants achieving Lupus Low Disease Activity State (LLDAS) with baseline Systemic Lupus Erythematosus Disease Activity Questionnaire (SLEDAI) ≥6
Time frame: Up to month 60
Number of participants achieving SLE Responder Index (SRI) - 4 with baseline SLEDAI ≥6
Time frame: Up to month 60
Number of participants with flares as assessed by SLEDAI flare index
Time frame: Up to month 60
Severity of participants with flares as assessed by SLEDAI flare index
Time frame: Up to month 60
Change from baseline in proteinuria
Time frame: Up to month 60
Change from baseline in estimated glomerular filtration rate (eGFR)
Time frame: Up to month 60
Change from baseline in Systemic Lupus International Collaborating Clinics (SLICC)/ACR (American College of Rheumatology) damage index
Time frame: Up to month 60
Percentage of participants achieving maintenance of drug-free DORIS remission
Time frame: Up to month 60
Percentage of participants achieving maintenance of LLDAS
Time frame: Up to month 60
Percentage of participants achieving maintenance of SRI-4
Time frame: Up to month 60
Time from first response to loss of response for drug-free DORIS remission
Time frame: Up to month 60
Time from first response to loss of response for LLDAS
Time frame: Up to month 60
Time from first response to loss of response for SRI-4
Time frame: Up to month 60
Time from baseline to first drug-free DORIS remission
Time frame: Up to month 60
Time from baseline to LLDAS
Time frame: Up to month 60
Time from baseline to SRI-4
Time frame: Up to month 60
Duration of drug-free status
Time frame: Up to month 60
Percentage of participants achieving DORIS remission regardless of drug-free status
Time frame: Up to month 60
Glucocorticoid used post-infusion for SLE treatment
Time frame: Up to month 60
Change of serum autoantibodies from baseline
Time frame: Up to month 60
Change in complement factor (C3 and C4) levels from baseline
Time frame: Up to month 60
Change from baseline in patient reported outcomes (PRO) as assessed by FACIT-Fatigue
Time frame: Up to month 60
Change from baseline in PRO as assessed by SF 36 v2 Acute
Time frame: Up to month 60
Change from baseline in PRO as assessed by EQ-5D-5L
Time frame: Up to month 60
Change from baseline in PRO as assessed by Patient Global Impression of Severity (PGI-S) Pain
Time frame: Up to month 60
Change from baseline in PRO as assessed by PGI-S Fatigue
Time frame: Up to month 60
Patient Global Impression of Change (PGI-C) Pain
Time frame: Up to month 60
PGI-C Fatigue
Time frame: Up to month 60
Number of participants with Adverse Events (AEs)
Time frame: Up to month 60
Number of participants with serious AEs (SAEs)
Time frame: Up to month 60
Number of participants with AESIs (AEs of Special Interest)
Time frame: Up to month 60
Number of participants with clinically significant laboratory abnormalities
Time frame: Up to month 60
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Started Jul 2025 (actual). Primary completion is estimated for May 2028, 34 months after the start.
Of 33 phase 2 interventional studies under Lupus Nephritis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 57. This study's planned 34 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zolacabtagene autoleucel
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company →